Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.
